Rigel Pharmaceuticals (RIGL) Share-based Compensation (2010 - 2025)

Rigel Pharmaceuticals' Share-based Compensation history runs 16 years deep, the most recent figure standing at $2.7 million for Q4 2025.

• On a quarterly basis, Share-based Compensation rose 126.66% year-over-year to $2.7 million in Q4 2025; TTM through Mar 2026 was $4.4 million, a 150.55% increase from a year earlier, with the FY2025 full-year figure at $12.7 million, up 19.92% from the prior year.
• Share-based Compensation retreated to $2.7 million in Q4 2025 per RIGL's latest filing, from $17.3 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $17.3 million in Q3 2025 and bottomed at -$10.3 million in Q4 2024.
• The 5-year median for Share-based Compensation is $769500.0 (2022), against an average of $1.4 million.
• Across the five-year window, Share-based Compensation plunged 633.16% in 2024 and soared 10849.37% in 2025, its largest moves.
• Year by year, Share-based Compensation stood at $2.3 million in 2021, then jumped by 74.43% to $4.1 million in 2022, then sank by 52.62% to $1.9 million in 2023, then plunged by 633.16% to -$10.3 million in 2024, then soared by 126.66% to $2.7 million in 2025.
• Per Business Quant, the three latest RIGL Share-based Compensation figures stand at $2.7 million (Q4 2025), $17.3 million (Q3 2025), and $418000.0 (Q2 2025).